Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?

Thyroid cancer (TC) is the most common endocrine malignancy, showing a rapid growth in its incidence during recent years. In 2013 the predicted number of all people with TC living in the USA was nearly 637,000, whereas estimated number of new cases diagnosed in 2016 is about 64,300. TC accounts for ~3.8% of all new cancer cases, but—due to a generally good prognosis—in 2016 this disease will count for no more than 2000 deaths (0.3% of all cancer mortality) (1).